Oral Mucositis Drugs Market Size, Share, Growth, and Industry Analysis by Type (Mouthwash, Pain Control Medication and Other Types), By Application (Chemotherapy, Radiotherapy and Others), Regional Insights and Forecast To 2032

• 

   Request a Free Sample To Get More Information on this Market

Oral Mucositis Drugs Market Report Overview

global oral mucositis drugs market size was USD 1.04 billion in 2023 and market is projected to touch USD 2.00 billion by 2032 at CAGR 7.5% during the forecast period.

Mucositis develops when cancer treatments damage the rapidly dividing epithelial cells that lining the gastrointestinal tract, leaving the mucosal tissue prone to ulceration and infection. Mucositis is most typically observed in the oral cavity. Oral mucositis affects around 40% of chemotherapy and 100% of radiation patients. Insufferable pain and inflammation, increased infection risk, starvation, dehydration, trouble speaking, and increased narcotic use are all serious OM consequences. If left untreated, these lesions can develop into life-threatening illnesses.

Oral mucositis is one of the most common and severe side effects of cancer treatment, particularly chemotherapy and radiation. It can cause a range of problems, including discomfort, nutritional concerns due to inability to eat, and an increased risk of infection due to open sores in the mucosa. It has a significant impact on the quality of life of the patient and has the potential to be dose-limiting.  Oral mucositis is diagnosed using a variety of procedures, including a biopsy and fungal testing. Some of the products used to treat OM include antiseptic mouth rinses, pain relievers, water-soluble lubricants, bland rinses, and mucosal coating agents. 

COVID-19 Impact: The Foot Restrictions Led to the Downfall of the Market

Pharmaceutical and biotech businesses, in collaboration with governments worldwide, are working to solve the COVID-19 outbreak, from vaccine research to planning for pharmaceutical supply chain issues. Currently, approximately 115 vaccine candidates and 155 molecules are in the R&D pipeline. Furthermore, commonly used drugs such as hydroxychloroquine have seen a dramatic increase in demand for the treatment of COVID-19. As many developed countries face a shortage of these drugs, the high demand for these drugs has created enormous opportunities for manufacturers of COVID-19 management drugs. As a result of the need for vaccines and treatment medications for COVID-19, the pharmaceutical and biotechnology industries are predicted to increase significantly in the future. This, in turn, is projected to have a substantial impact on the oral mucositis medicine market.

LATEST TRENDS

"Growing Research and Development in Developing New Drugs to Inflate the Market Demand"

Increasing research into creating new oral mucositis medications is also anticipated to spur market expansion during the anticipated time frame. For instance, Suramin, a 100-year-old medication formerly used to treat African sleeping sickness, was modified in May 2020 by experts at the University of Arizona College of Pharmacy to combat oral mucositis and diabetic foot ulcers. This innovative technique could help thousands of people whose current treatment options are either ineffective completely or intrusive and painful.

Additionally, expanding clinical trials and implementing collaboration strategies are improving the pipeline of oral mucositis treatments. The introduction of mucoadhesive oral protectants, which can form a protective hydrogel coating over the oral mucosa during cancer therapies, is another goal of significant investments being made by a number of key stakeholders in research and development. This is also contributing to the market's bullish outlook.

Oral Mucositis Drugs Market Segmentation

• By Type

Based on type; the oral mucositis drugs market is divided into mouthwash, pain control medication and others.

Pain control medication is the leading part of the type segment.

• By Application

Based on the application; the oral mucositis drugs market is divided into chemotherapy, radiotherapy and others.

Radiotherapy is the leading part of the application segment.

DRIVING FACTORS

"Rising Prevalence of Head and Neck Cancer to Multiply the Drug Utilization"

The annual incidence of HNC in the United States and Europe is roughly 150,000 to 750,000 cases, respectively. Severe Oral Mucositis (SOM) will occur in 60 to 70% of these patients. Oral mucositis is caused by the negative effects of radiation and cytotoxic chemotherapy drugs on the oral mucosa. According to the National Institutes of Health, about 400,000 persons in the United States are diagnosed with oral mucositis each year. The global market for oral mucositis drugs is expanding in tandem with the increasing frequency of cancer patients. As a result, demand for oral mucositis therapy is fast increasing, which will fuel market expansion throughout the forecast period.

"Extensive Utilization of Radiation and Chemotherapy to Enhance the Market Demand"

The rising use of radiation therapy and chemotherapy to treat cancer, which destroy the rapidly dividing cells in the mucous membranes and cause inflammation and ulceration, is primarily driving the market for oral mucositis drugs. Furthermore, rising incidences of buccal cavity infections due to various risk factors, such as poor lifestyle habits, smoking, poor oral hygiene, and so on, are driving market growth. Furthermore, the widespread use of powerful medications, such as anti-inflammatory drugs and topical pain relievers, to reduce tissue swelling and provide symptom relief is acting as a significant growth-inducing factor.

RESTRAINING FACTORS

"Stringent Approvals to the Products to Restrain the Market Growth"

The stringent clearances associated with oral mucositis products are projected to stymie market growth. However, the issuance of patents and lengthy stringent approvals for products from regulatory bodies such as the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH), among others, is slowing the oral mucositis drugs market growth.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market
•  

Oral Mucositis Drugs Market Regional Insights

"North America to Lead the Market with Prominent Manufacturers and Rising Cancer Patients"

Because of the growing frequency of chronic lifestyle-related disorders in the region, North America dominates the oral mucositis drugs market. It has the greatest market share, which is mostly due to the rising occurrence of head and neck cancer in the country. According to the American Society of Clinical Oncology's (ASCO) 2021 report, around 4% of persons in the United States had head and neck cancer, with an estimated 66,630 people developing the disease. Cancer cases in the United States are likely to boost the expansion in oral mucositis drugs market share.

Oral mucositis affects about 500,000 people in the United States each year, creating a new market in which unmet health care needs are predominantly a long-standing issue. Furthermore, significant funding and investment in the development of new products to treat the condition are expected to drive oral mucositis drugs market growth in the United States.

KEY INDUSTRY PLAYERS

"Key Industry Players to Promote the Market Expansion"

The market's expansion was significantly impacted by the techniques employed by market participants in recent years, such as extensions. The report covers details and information about the firms and their interactions with the market.

LIST OF TOP ORAL MUCOSITIS DRUGS COMPANIES

• 3M Healthcare (U.S.A)
• GSK (U.K)
• Pfizer (U.S.A)
• Colgate-Palmolive
• Norgine (The Netherlands)
• Sobi (Sweden)
• Bausch Health (Canada)
• EUSA Pharma (U.K)
• Camurus (Sweden)
• Clinigen Group (U.K)
• Helsinn Healthcare (Switzerland)
• Alliance Pharma (U.S.A).

REPORT COVERAGE

This report covers a comprehensive backdrop analysis, an assessment of the parent market, intensive study in the market dynamics. Past historical, current, and projected size of the market from the point of both value and volume. Researching of recent industry developments,  deep study on market shares and strategies of major players and the emerging niche segments and regional market areas are covered in the report.